Phase III VITaL trial will test whether functional lung avoidance improves quality of life

VITaL will randomize 165 patients with stage III NSCLC to standard or CT ventilation-guided RT and compare three-month quality of life.

KEY POINTS

  • The TROG 21.08 VITaL trial (NCT06127654) is an ongoing multicenter, double-masked, randomized phase III study designed to enroll 165 patients with stage III non-small cell lung cancer. It will compare standard radiotherapy with functional lung-sparing treatment guided by CT ventilation imaging, with patient-reported quality of life as the primary endpoint.
  • Eligible patients must have ECOG performance status 0–2 and receive curative-intent RT using 60 Gy in 30 fractions or 55 Gy in 20 fractions, with or without concurrent chemotherapy and subsequent PD-1/PD-L1 inhibition. Exclusion criteria include interstitial lung disease, previous lung irradiation, and specified prior treatments for the current cancer.
  • CT ventilation maps will be generated from paired inspiratory and expiratory breath-hold CT scans, allowing identification of highly and poorly ventilated lung regions. Each patient will have two plans generated: a conventional anatomical plan and a functional avoidance plan designed to redirect dose away from better-ventilated lung while maintaining acceptable target coverage and conventional OAR constraints.
  • Additional eligibility requirements include standard-plan lung-minus-GTV V20Gy ≥16% and sufficient respiratory volume change for ventilation mapping: more than 500 cc or 10% between expiratory and inspiratory CT images. Patients will be randomized 1:1, with stratification by treatment center, concurrent chemotherapy, and planned adjuvant immunotherapy.
  • The primary endpoint is the change in the Functional Assessment of Cancer Therapy–Lung Trial Outcome Index (FACT-L TOI) from baseline to three months after RT. The trial is powered to detect a 5-point between-arm difference, considered clinically meaningful, with 142 evaluable patients providing 80% power; planned enrollment of 165 accounts for approximately 15% attrition.
  • Secondary endpoints include physician-assessed pulmonary, esophageal, and cardiac toxicity using CTCAE v5.0, changes in FEV1, receipt and completion of consolidation immunotherapy, disease progression, overall survival, and cost-effectiveness. Follow-up will extend to 36 months, including an economic assessment using quality-adjusted life-years.
  • Previous functional lung avoidance studies provide the rationale, including a reported 8% versus 32% grade ≥2 pneumonitis rate in a conventional-fractionation subgroup of an earlier phase II study. These are not VITaL results: the current publication describes the protocol only, with recruitment underway and full accrual projected for December 2029.

CLINICAL TAKEAWAY

VITaL addresses whether protecting the most functional lung regions, rather than relying exclusively on conventional anatomical dose constraints, can meaningfully improve quality of life after definitive RT for stage III NSCLC. Its randomized, double-masked design and patient-centered primary endpoint should provide more reliable evidence than previous functional avoidance studies, but no clinical benefit has yet been demonstrated by this trial.

SOURCE

Clinical and Translational Radiation Oncology

Browse more research Suggest a correction